Previous 10 | Next 10 |
Projected Cash Runway into the First Quarter of 2022 Borrowed $11 Million from Term Loan Facility WAYNE, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today an...
WAYNE, Pa., March 31, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (“SVB”) pursuant to which Aclaris has borrowed $...
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this Read more ...
Aclaris Therapeutics, Inc. (ACRS) Q4 2019 Earnings Conference Call February 25, 2020, 05:00 PM ET Company Participants Kamil Ali-Jackson - Chief Legal Officer Neal Walker - President and CEO Frank Ruffo - CFO David Gordon - Chief Medical Officer Joe Monahan - EVP, Research an...
Penny Stocks To Watch After Coronavirus Comments This topic continues to captivate headlines: the coronavirus. A number of penny stocks have greatly benefited from speculation on “what’s next” for the virus spread. Today may have opened a bigger can of worms for investor...
Aclaris Therapeutics (NASDAQ: ACRS ): Q4 GAAP EPS of -$0.45 misses by $0.30 . More news on: Aclaris Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Positive Preliminary Results from Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor Projected Cash Runway into the Third Quarter of 2021 Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., Feb. 25, 2020 (GLOBE...
WAYNE, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the fourth quarter and full year 2019, Tuesday, February 25 th , af...
AIM ImmunoTech (NYSEMKT: AIM ) +20% on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus. More news on: AIM ImmunoTech Inc., TransEnterix, Inc., Shopify Inc., Stocks on the move, , Read more ...
WAYNE, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present a company overview at the SVB Leerink 9th Annual Global Healthcare Confere...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...